Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The closing price of Iovance Biotherapeutics Inc (NASDAQ: IOVA) was $1.75 for the day, down -4.37% from the previous closing price of $1.83. In other words, the price has decreased by -$4.37 from its previous closing price. On the day, 7.66 million shares were traded.
Ratios:
Our analysis of IOVA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.64 and its Current Ratio is at 4.18. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 23 ’25 when Puri Raj K. bought 5,600 shares for $1.74 per share. The transaction valued at 9,743 led to the insider holds 206,852 shares of the business.
Vogt Frederick G bought 25,000 shares of IOVA for $42,250 on May 14 ’25. The Interim CEO & General Counsel now owns 374,646 shares after completing the transaction at $1.69 per share. On Nov 12 ’24, another insider, Maynard Ryan D, who serves as the Director of the company, sold 50,000 shares for $10.06 each. As a result, the insider received 503,000 and left with 7,500 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 2.75 while its Price-to-Book (P/B) ratio in mrq is 0.76.
Stock Price History:
Over the past 52 weeks, IOVA has reached a high of $12.51, while it has fallen to a 52-week low of $1.64. The 50-Day Moving Average of the stock is -38.81%, while the 200-Day Moving Average is calculated to be -74.50%.
Shares Statistics:
A total of 333.93M shares are outstanding, with a floating share count of 271.58M. Insiders hold about 18.67% of the company’s shares, while institutions hold 64.00% stake in the company.
Earnings Estimates
A comprehensive evaluation of Iovance Biotherapeutics Inc (IOVA) is underway, with the input of 10.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.25, with high estimates of -$0.18 and low estimates of -$0.29.
Analysts are recommending an EPS of between -$0.87 and -$1.18 for the fiscal current year, implying an average EPS of -$1.06. EPS for the following year is -$0.71, with 10.0 analysts recommending between -$0.12 and -$1.04.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 11 analysts. It ranges from a high estimate of $75.9M to a low estimate of $55.16M. As of the current estimate, Iovance Biotherapeutics Inc’s year-ago sales were $31.11MFor the next quarter, 11 analysts are estimating revenue of $78.32M. There is a high estimate of $84.01M for the next quarter, whereas the lowest estimate is $73.81M.
A total of 11 analysts have provided revenue estimates for IOVA’s current fiscal year. The highest revenue estimate was $300.4M, while the lowest revenue estimate was $261.65M, resulting in an average revenue estimate of $287.11M. In the same quarter a year ago, actual revenue was $164.07MBased on 11 analysts’ estimates, the company’s revenue will be $484.09M in the next fiscal year. The high estimate is $634.1M and the low estimate is $375M.
